Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody), a humanized monoclonal antibody, selectively neutralizes IL-17A and IL-17F, which promote osteogenic differentiation in human periosteum-derived cells (hPDC), and consequently inhibits inflammat
CAS Nummer:
[1418205-77-2]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten